| Value | ₹1,060 Cr |
|---|
BSE filing, NSE: NATCOPHARM. Summary written from the filing by ALFA Finder's alert engine.
Natco Pharma Ltd: key numbers
- Share price
- ₹793.00
- Market cap
- ₹15,556 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.6×Sector 46.1×
- Promoter holding
- 49.39%-0.03% QoQ
- FII holding
- 15.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Capital Structure Change
Natco Pharma's ₹1,279.4 Crore rights issue closed on October 22, 2026. Shares were priced at ₹750 each on a ₹2 face value.
- Value
- ₹1,279 Cr
Natco Pharma Product Launch
Natco Pharma launches Carboplatin Injection, a Paraplatin® generic, in the U.S. market via its subsidiary. The oncology product addresses a critical U.S. supply shortage.
Natco Pharma Other Announcement
Natco Pharma Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance submission.
Natco Pharma Share Pledge
Promoter V.C. Nannapaneni pledged 850,000 shares of Natco Pharma, valued at ₹67.10 Crore. This pledge creation increases encumbrance on promoter shareholding.
- Value
- ₹67.10 Cr
Natco Pharma Fund Raise of ₹2,000 Cr
Natco Pharma shareholders approved fund raising of up to Rs. 2,000 Crore through various instruments, along with other routine AGM resolutions.
- Value
- ₹2,000 Cr
Natco Pharma Annual General Meeting
Natco Pharma held its 43rd Annual General Meeting on September 30, 2026. Shareholders approved all agenda items, including a fund-raising authorisation limit of Rs. 2,000 Crore.
Other merger & restructuring announcements
All →Reliance Industries Merger & Restructuring
Reliance disclosed that UK registrar published a gazette notice for voluntary strike-off of step-down subsidiary Hamleys (Franchising) Limited. HFL contributed 0.0048% of consolidated turnover, so impact is negligible.
Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals